Pharmaceutical market and Diabetes market worldwide.

11,459 views

Published on

3 Comments
5 Likes
Statistics
Notes
No Downloads
Views
Total views
11,459
On SlideShare
0
From Embeds
0
Number of Embeds
12
Actions
Shares
0
Downloads
495
Comments
3
Likes
5
Embeds 0
No embeds

No notes for slide

Pharmaceutical market and Diabetes market worldwide.

  1. 1. GLOBAL PHARMACEUTICAL MARKET1. Growing at a CAGR of around 8%, the global pharmaceutical market is forecasted to reach US$ 1043.4 Billion in 2012.2. North America remains the largest pharmaceutical market constituting 42.8% of the global sales in 2007. Growth in the region is however expected to slow down in near future owing to patent expiration of key drugs and increased prevalence of generics.3. In Europe, growth in the top five markets is expected to remain sluggish in next five years. Emerging markets in Central and Eastern Europe is however expected to drive growth in future.4. A large untapped population and strong economic growth in major countries is “ “The global pharmaceutical market value is expected to expand expected to make Asia-Pacific the most lucrative pharmaceutical market in future. over $1.1 trillion5. Growth in the Latin American markets is expected to be strong with Brazil and USD by 2014,” Mexico amongst the most emerging pharmaceutical markets in the world.6. Dwindling drug pipelines and patent expiration of a number of blockbuster drugs may challenge the growth of global pharmaceutical market in future. ”
  2. 2. Diabetes , is a group of metabolic diseases in whicha person has high blood sugar, either because the bodydoesnot produce enough insulin, or because cells do notrespondto the insulin that is produced.There are three main types of diabetes:Type 1 diabetes: results from the bodys failure to produceinsulin, and presently requires the person to inject insulin. {ORinsulin-dependent diabetes mellitus, (IDDM )} & juvenilediabetes.)Type 2 diabetes: results from insulin resistance, a condition inwhich cells fail to use insulin properly, sometimes combinedwith an absolute insulin deficiency. {OR non-insulin-dependentdiabetes mellitus, NIDDM)} & adult-onset diabetes.)Gestational diabetes: is when pregnant women, who havenever had diabetes before, have a high blood glucose levelduring pregnancy. It may precede development of type 2 DM.
  3. 3. GLOBAL DIABETES POPULATIONGlobally as of 2010 it is estimated that there are 285million people diabetes with type 2 making up about 90%of the cases.• it is estimated that by 2030, this number will almost double.•It is more common (especially type 2) in the more developed countries.• it is expected that in Asia and Africa, where most patients will probably be found by 2030.•The increase in incidence of diabetes in developing countries follows the trend of urbanization and lifestyle changes, perhaps most importantly a "Western-style“ diet.
  4. 4. PREVALENCE OF DIABETES COUNTRY WISE
  5. 5. GLOBAL DIABETES MARKET The global market for products in the management ofdiabetes currently stands at $41 billion and is on pace togrow to over $114 billion by 2018. Oral anti-diabetics were the leading category of drugsin 2010 and showed a growth rate of 6.3% from the totalglobal sales.The total sales for insulin products increased significantlyas well.
  6. 6. Global Diabetes Market Trends & Future Forecast USA controls more than 50% of the total Diabetes Drug market share in 2009. • Global Insulin Market is estimated to reach around US$ 17 Billion by 2013. • China will have the second highest Insulin market share by 2012 replacing Germany. • DPP-IV Inhibitors is predicted to be more than US$ 5 Billion market by 2015. • LP-1 Agonists, market is forecasted to cross US$ 6 Billion mark by 2015 . • Novorapid is the blockbuster Insulin of Novo Nordisk it is expected to cross US$ 3 Billion by 2015.
  7. 7. Global Diabetes Market Trends & Future Forecast • Yet to launched Degludec and Degludec Plus is expected to be blockbuster Insulin and cross US$ 4 Billion and US$ 6 Billion respectively by 2030. • Januvia is proving a blockbuster of DPP – IV Inhibitors segment expected to be more than US$ 4 Billion by 2017 . •Last year launched Victoza and yet to be launched Exenatide LAR is going to be blockbuster GLP-1 Agonists . • China diabetes drug market has crossed the figure of Yuan 10 Billion by 2009. • Japan Insulin market is expected to be more than US$ 1 Billion by 2010.
  8. 8. Global DIABETES TOP PLAYERS
  9. 9. PRODUCTS STRONG IN DIABETESMARKETAnti-diabetic products include glucose meters, lancets, test strips, continuous blood glucose meters, insulin, insulin pumps, syringes and other insulin delivery devices and anti-diabetic drugs.The bulk of product revenues come from three segments - test strips, insulin and anti-diabetic drugs - which will remain the largest sources of product revenues over the next ten years.The most significant growth, however, will come from the nascent segment of continuous blood glucose monitors, which provide significantly added clinical benefit at only a modestly higher cost compared to standard blood glucose meters.
  10. 10. NEW MOLECULES DEVELOPING FORDIABETESUniversity of Technology, Sydney. UTS researchers have identified molecules secreted by a parasitic worm that preventthe development of Type 1 diabetes in mice.A commercial version of the product is currently being developed for use in humans.Researchers at the Stanford University School of Medicinehave identified a key molecular pathway responsible for thenatural decrease in the proliferation of insulin-producing cellsthat occurs as a person ages. Artificially activating thispathway, which is normally not functional in adults, may be anew way to combat diabetes.
  11. 11. INDIAN DIABETES MARKETWith around 51 million diabetic patients, India promises to beamongst the most lucrative diabetes markets in the world. In2009, the total sales of insulin and non-insulin anti-diabeticsreached $424 million, according to the findings of a news reportadded to the offering of Research and Markets. REPORT HIGHLIGHTS• A growing drug treated population coupled with the launch of several new drugs will drive the Indian diabetes market to $1.4 billion by 2015.• In 2009, the market for non-insulin anti-diabetics was worth $306 million. This represented a highly fragmented market with domestic diabetes care firm USV being the leading player with a 14% share.• USV’s Glycomet GP (glimepiride+metformin) was the leadingdrug in the non-insulin anti-diabetics market with sales worth nearly
  12. 12. INDIAN DIABETES MARKET•The authors expect around 15 new drugs to be launched in the non-insulin anti-diabetics market in the next five years. Seven of them are expected to be in the DPP-IV inhibitor and GLP-1 agonist classes.• The insulin market was worth $117 million in 2009. US health care major Abbott Laboratories was Indias biggest player accounting for 61% of the total sales.• Sanofi-Aventis’ Lantus (insulin glargine) represented one of the fastest growing drugs in the last five year and registered sales worth nearly $11 million in 2009• The total number of diabetes patients in India is expected to reach 87 million by 2030. Around 56% of these patients will be from urban regions of the country.
  13. 13. INDIAN DIABETES TOP PLAYERS
  14. 14. THE INDIAN MARKET OPPORTUNITY•World’s largest diabetes patient pool•Success of newly launched drugs•Increasing diagnosis and drug treated rates•A rapidly growing marketIn 2010, total sales of insulin and oral anti-diabetics in Indiareached INR 28 billion, of which, the market for oral anti-diabetics was worth INR 17 billion**. With the number ofdiabetics increasing, the market, over the next five years, willbe driven by the strong uptake of insulin analogs.Januvia is proving a blockbuster of DPP – IV Inhibitors segment expected to be more than US$ 4 Billion by 2017 (GLOBALLY)

×